Amgen Inc Stock Deemed Overvalued by GF Value Estimate
Amgen Inc (AMGN) stock has experienced significant price fluctuations in recent times. On September 22, 2026, its shares increased by 4.3%, bringing the current price to $410.24. Throughout the past year, the stock has seen a remarkable rise of 47.4%, although it faced a decline of 6.6% over the last month.
The GF Value ™ verdict indicates that Amgen is currently overvalued by approximately 11.7%. This means investors may be paying more than what the underlying fundamentals suggest the stock is worth. The strong price performance year-to-date and over the past year may not be sustainable if the fundamentals do not align with the current market price.
The forward P/E of 16.8x suggests a potentially more favorable valuation in the future, but this remains to be seen in light of current market conditions. Amgen's GF Score ™ of 86/100 indicates a strong overall performance, with its highest ranks in profitability and growth.